Drugs / Docetaxel-PM
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03585673 | Jun 2018 → Mar 2020 | esophageal squamous cell carcinoma, metastatic malignant neoplasm | Sung Yong Oh | Unknown | No outcome recorded |
| Phase 2 | NCT02639858 | Oct 2015 → Sep 2020 | head and neck squamous cell carcinoma | Samyang Biopharmaceuticals Corporation | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02982395 | Jan 2017 → Aug 2018 | urinary bladder carcinoma | Samyang Biopharmaceuticals Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Docetaxel-PM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03585673 ↗ |
| Known as | NanoxelM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982395 ↗ |
| Route | Intravenous | “Docetaxel-PM 75mg/m2 IV infusion” NCT02639858 ↗ |